The combination of acute phase marker monitoring and the "T2Candida" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Acute-phase biomarkers dynamics - procalcitonin
Timeframe: 8 days
Acute-phase biomarkers dynamics - interleukin-6
Timeframe: 8 days
Acute-phase biomarkers dynamics - interleukin-10
Timeframe: 8 days
Acute-phase biomarkers dynamics - Presepsin
Timeframe: 8 days
Acute-phase biomarkers dynamics - C-reactive protein
Timeframe: 8 days
Acute-phase biomarkers dynamics - 1,3-β-D-glucan
Timeframe: 8 days
Acute-phase biomarkers dynamics - pentraxin 3
Timeframe: 8 days
T2Candida test
Timeframe: One-time measurement at the enrolment into the study
Lipopolysaccharide binding protein
Timeframe: One-time measurement at the enrolment into the study